Translational
Also known as: Level 1, Translational Stage, Early-stage grant funding
The first funding level in the GAITS Funding Readiness Framework — mission-driven funding for teams with a defined unmet need and a plausible technical approach, where the primary risk is scientific and translational feasibility.
Full Definition
Translational funding marks the point where a team moves from scientific exploration to structured development with an articulated path toward clinical or commercial use. Funders at this stage are evaluating scientific and translational feasibility — the core question is whether the technology can be shown to work in a meaningful sense, not whether it can be commercialised.
In the GAITS Funding Readiness Framework, Translational is Level 1 of 5. The primary risk at this stage is scientific and translational: does the underlying approach address a real unmet need, and is there a credible path from current evidence to a validated proof of concept? Funders are typically mission-driven — government agencies, research councils, and philanthropic bodies — rather than commercial investors.
Typical instruments include SBIR/STTR Phase I (US), Innovate UK Smart Grants and NIHR i4i Feasibility Awards (UK), and EIC Pathfinder grants (EU). Teams at this stage should be able to articulate the clinical problem, describe the technical approach, and explain why the proposed work is the right next step.
A team with a novel biosensor concept for early sepsis detection applies for an SBIR Phase I grant. Their application describes a defined clinical problem, a technical approach with supporting bench data, and a proposed feasibility study to test performance in patient samples. The primary risk is whether the technology can achieve the sensitivity and specificity targets in a clinically relevant format. This is a Translational-stage application: the funder is evaluating scientific plausibility and the team's ability to execute the feasibility work, not the commercial pathway.